Caribou Biosciences Balance Sheet Health
Financial Health criteria checks 5/6
Caribou Biosciences has a total shareholder equity of $122.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $175.4M and $53.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$139.34m |
| Equity | US$122.18m |
| Total liabilities | US$53.19m |
| Total assets | US$175.37m |
Recent financial health updates
Here's Why Caribou Biosciences (NASDAQ:CRBU) Must Use Its Cash Wisely
Dec 31
Here's Why We're Watching Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Situation
Sep 06Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans
Jan 10Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth
Feb 24Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth
Sep 16Recent updates
Caribou Biosciences: A Much Anticipated Data Readout Does Not Quite Get My Buy
Nov 03Caribou Biosciences: CB-010 And Other CAR-Ts Pressing Forward Despite Initial Data
Jan 02Here's Why Caribou Biosciences (NASDAQ:CRBU) Must Use Its Cash Wisely
Dec 31Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares Bounce 25% But Its Business Still Trails The Industry
Nov 05Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing
Sep 30Here's Why We're Watching Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Situation
Sep 06Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Share Price Boosted 39% But Its Business Prospects Need A Lift Too
Jul 26Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential
Jul 03Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding
Jun 05Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value
Apr 18More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%
Apr 17Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up
Feb 15Caribou Biosciences: Under The Radar With Catalysts Approaching
Feb 01Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans
Jan 10Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues
Nov 18Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth
Feb 24Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability
Oct 12Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth
Sep 16Caribou Biosciences: Potential To Change CAR-T Landscape
Aug 01Crispred CAR-T Cells In The Clinic
May 19Financial Position Analysis
Short Term Liabilities: CRBU's short term assets ($145.2M) exceed its short term liabilities ($25.4M).
Long Term Liabilities: CRBU's short term assets ($145.2M) exceed its long term liabilities ($27.8M).
Debt to Equity History and Analysis
Debt Level: CRBU is debt free.
Reducing Debt: CRBU has no debt compared to 5 years ago when its debt to equity ratio was 8.8%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CRBU has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CRBU has less than a year of cash runway if free cash flow continues to reduce at historical rates of 26.7% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/10 13:40 |
| End of Day Share Price | 2026/03/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Caribou Biosciences, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Leah Rush Cann | Brookline Capital Markets |
| Yigal Nochomovitz | Citigroup Inc |